share_log

ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q1 FINANCIAL RESULTS

ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q1 FINANCIAL RESULTS

ARCPOINT 將舉辦電話會議討論2024年第一季度財務業績
GlobeNewswire ·  05/23 19:00

Greenville, South Carolina, May 23, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the "Company" or "ARCpoint") a leading US-based franchise system providing drug testing, alcohol screening, DNA and direct to consumer ("DTC") clinical lab testing services, announces that it will host a conference call at 11am Eastern time, Friday, May 24, 2024 to review the Company's Q1 financial results for the period ending March 31, 2024.

2024年5月23日南卡羅來納州格林維爾(GLOBE NEWSWIRE)——ARCpoint Inc.(TSXV:ARC)(以下簡稱“公司”或“ARCpoint”)是一家領先的總部位於美國的特許經營系統,提供藥物檢測、酒精測試、DNA和直接面向消費者(“DTC”)的臨床實驗室檢測服務,並宣佈將於2024年5月24日東部時間上午11點舉行電話會議,審核截至2024年3月31日的第一季度財務業績。

The dial-in number for the conference call is as follows:

電話會議的撥號號碼如下:

Canada / USA Toll Free 1-844-763-8274
International Toll +1-647-484-8814

加拿大/美國免費電話1-844-763-8274
國際來電+1-647-484-8814

Callers should dial in 5 – 10 min prior to the scheduled start time and ask to join the ARCpoint call:

撥打電話應在預定開始時間的5-10分鐘前,並要求加入ARCpoint電話會議:

ARCpoint President and CEO, John Constantine commented "In addition to the progress we've made in reducing costs, we are encouraged by the improvement in revenues for our AFG Services Group, which is largely dominated by our technology platforms MyARCPointLabs and Total Reporting".

ARCpoint總裁兼首席執行官約翰·康斯坦丁表示:“除了在降低成本方面取得的進展外,我們還對AFG服務集團的營收增長感到鼓舞,該集團主要由我們的技術平台MyARCPointLabs和Total Reporting平台主導。

As reported April 29, 2024, throughout April 2024, the Company enacted reductions in headcount as well as to operational and administrative costs that are expected to result in annualized savings of approximately USD$530 thousand in staffing costs and USD$440 thousand in operational and administrative costs. These reductions are in addition to the staffing and operational cuts totalling USD$2.0 million as previously reported by the Company in its news releases dated March 8 and October 17, 2023.

如2024年4月29日所報道的,公司在2024年4月期間實施了裁員以及削減預計將爲公司帶來每年約53萬美元的員工成本和約44萬美元的運營和行政成本的措施。這些削減措施是公司早前在其2023年3月8日和10月17日的新聞發佈中報道的2,000萬美元的人員和運營削減的補充。

AFG Services, which primarily provides clinical testing and software services that support the Company's franchise systems as well as other direct business to business customers with it's Total Reporting platform, increased revenues by 19% to USD$582 thousand in Q1 2024, versus USD$490 thousand in Q4 2024.

AFG服務公司主要提供支持公司特許經營體系以及其他直接面向企業客戶的臨床測試和軟件服務,並通過其Total Reporting平台,以增加19%的Q1 2024營收,達到58.2萬美元,而Q4 2024的收入爲49萬美元。

Mr. Constantine concluded, "With most of the development expense and heavy lifting of the launch of our technology platforms behind us, we are now positioned to expand the use of these platforms to new users. In particular, we are working hard to leverage MyARCPointLabs to create a healthcare ecosystem that will drive more business to our franchisees and expand our distribution network through new partnerships".

康斯坦丁先生總結道:“隨着我們的技術平台發展和推出的重擔已經大部分完成,我們現在已經有能力將這些平台的使用擴展到新用戶中。特別是,我們正在努力利用MyARCPointLabs創建一個醫療生態系統,以爲我們的特許經營商帶來更多業務,並通過新的合作伙伴擴大我們的分銷網絡。”

On July 10, 2023 the Company reported that it had launched its new consumer e-commerce platform, MyARCpointLabs. ("MAPL") MAPL was developed to make it easier for the Company's franchisees to attract and better serve individual healthcare consumers and for a greater number of consumers to purchase the Company's products and services more easily. By year end of 2023, every ARCpoint franchised location had MAPL integrated into their location and interfaced with their local website. The combination of all ARCpoint locations having MAPL deployed and an increase in monthly reoccurring fees for users to access MAPL, helped MAPL revenue increase by 23% to USD$223 thousand in Q1 2024, versus USD$181 thousand in Q4 2023.

2023年7月10日,公司宣佈推出了新的消費者電子商務平台MyARCpointLabs(“MAPL”)。MAPL是爲了讓公司的特許經營商更輕鬆地吸引和更好地服務於個別醫療保健消費者,並讓更多的消費者更輕鬆地購買公司的產品和服務。到2023年年底,每個ARCpoint特許經營位置都將MAPL集成到其位置,並與其本地網站進行接口對接。所有ARCpoint位置都部署了MAPL並且月度固定費用增加,這有助於MAPL營收在Q1 2024達到了22.3萬美元,而Q4 2023爲18.1萬美元,增長了23%。

MAPL provides interface support with various other healthcare organizations and acts as the operations tool within the franchise system. The technology virtualizes the Company's consumer business model allowing for the expansion of the Company's footprint to other entities beyond traditional ARCpoint facilities and enabling franchisees to generate revenue prior to having a brick and mortar facility. MAPL also allows for the linking of diagnostic testing services with virtual physicians, telehealth organizations and other healthcare system constituents, such as independent pharmacies.

MAPL可以與各種其他醫療保健組織進行接口支持,並充當特許經營體系內的運營工具。這種技術使公司的消費者業務模式虛擬化,從而將公司的影響擴大到傳統的ARCpoint設施之外的其他實體,並使特許經營商可以在擁有實體設施之前產生收入。MAPL還允許將診斷測試服務與虛擬醫生、遠程醫療組織和其他醫療保健系統成員(例如獨立藥房)進行鏈接。

On November 21, 2023, the Company further announced that it had implemented a new application programming interface ("API") with MD Care Group LLC, ("MD Care Group") a telehealth company, which provides consumers with cost-effective, virtual access to health care through a national network of thousands of board-certified physicians and health care providers. This allows ARCpoint customers to connect with MD Care Group's doctors, through MAPL, to discuss results from ARCpoint diagnostic tests or other medical concerns they may have. This opens the door for future opportunities for the creation of virtual primary care and urgent care centers anywhere ARCpoint services can be accessed.

2023年11月21日,公司進一步宣佈,已與MD Care Group LLC(“MD Care Group”)建立了新的應用程序編程接口(“API”),後者是一家通過數千名董事會認證的醫生和醫療保健提供者國家網絡提供消費者成本效益、虛擬訪問醫療保健。這使得ARCpoint客戶可以通過MAPL與MD Care Group的醫生聯繫,以討論ARCpoint診斷測試的結果或其他醫療問題。這爲在ARCpoint提供服務的任何地方創建虛擬初級保健和急診中心的未來機會打開了大門。

The Company's other technology platform, Total Reporting, is the Company's Business to Business portal. Total Reporting helps ARCpoint's franchisees to market more services, such as background checks and employer physicals through an efficient, single sign-on integrated platform. In Q1 2024, as a result of increased volumes and usage uptake, Total Reporting revenue increased by 12% to $324 thousand, versus $289 Thousand in Q4, 2023."

公司的另一個技術平台Total Reporting是公司的B2B門戶網站。Total Reporting通過一個高效的單一登錄集成平台,幫助ARCpoint的特許經營商營銷更多的服務,例如背景調查和僱主體檢。由於使用量和使用率的增加,Q1 2024的Total Reporting收入增長了12%,達到32.4萬美元,而Q4 2023爲28.9萬美元。

For Q1 2024, ARCpoint Franchise Group revenues declined to USD$1.2 million versus USD$1.5 million in Q4 2023 as the result of lower recognition and amortization of upfront franchising. ARCpoint Franchise Group revenue consists primarily of royalties and Brand Fund contributions based on a percentage of sales reported by franchise labs. Revenue generated from this segment also includes franchise fees paid by franchisees and initial clinical, training and technology setup fees paid by new franchisees.

截至2024年3月31日,ARCpoint特許經營集團的收入從2023年Q4的150萬美元下降到了120萬美元,這是由於較低的預付特許經營費用確認和攤銷而導致的。ARCpoint特許經營集團的收入主要是基於特許實驗室報告的銷售額所涉及的特許權和品牌基金貢獻的百分比。從這個部門產生的營收還包括由特許經營者支付的特許經營費用以及新特許經營者支付的初始臨床、培訓和技術設置費用。

As at March 31, 2024, the Company had total cash on hand of approximately US$0.35 million, comprised of US$0.34 million in unrestricted cash and cash equivalents and US$13,548 in Brand Fund restricted cash. Use of Brand Fund restricted cash is at the Company's discretion and is used to increase sales and the brand presence of the Company's entities and franchisees.

截至2024年3月31日,公司手頭的現金總額約爲35萬美元,其中無限制的現金及現金等價物爲34萬美元,品牌基金限制的現金爲13,548美元。品牌基金限制的現金使用由公司自行決定,用於增加公司實體和特許經營商的銷售和品牌存在。

All results below are reported under International Financial Reporting Standards and in US dollars.

以下所有結果均按照國際財務報告準則和美元報告。

Summary of 2024 Q1 Financial Results

2024年第一季度財務業績摘要

  • Total revenues for the three months ended March 31, 2024, were $1.6 million compared to $1.7 million for the three months ended March 31, 2023. The decrease in revenue for Q1 2024 versus Q1 2023 was primarily due to lower royalty and franchising revenues due to the pull back of COVID testing across the country offset by an increase in support service revenues provided to franchisees and lab services.
  • Net loss for the three months ended March 31, 2024, was $1.5 million compared to a net loss of $2.1 million for the three months ended March 31, 2023. The decrease in loss for Q1 2024 versus Q1 2023 was primarily due to a decrease in salary and wages of $0.7 million and decrease in general and administrative costs of $0.1 million.
  • Operating cash flow for the three months ended March 31, 2024 was negative $1.3 million compared to negative $1.2 million for the three months ended March 31, 2023.
  • EBITDA for the three months ended March 31, 2024, was negative $1.2 million compared to negative $1.8 million for the three months ended March 31, 2023.
  • Adjusted EBITDA for the three months ended March 31, 2024, was negative $1.0 million compared to negative $1.1 million for the three months ended March 31, 2023.
  • 截至2024年3月31日三個月的總收入爲160萬美元,而截至2023年3月31日三個月的總收入爲170萬美元。Q1 2024與Q1 2023的收入下降主要是由於全國性的COVID測試推出。
  • 截至2024年3月31日三個月的淨虧損爲150萬美元,而截至2023年3月31日三個月的淨虧損爲210萬美元。Q1 2024與Q1 2023虧損減少主要是由於薪水和工資減少700萬美元和一般和行政成本減少100萬美元。
  • 截至2024年3月31日三個月的經營現金流爲負130萬美元,而截至2023年3月31日三個月的經營現金流爲負120萬美元。
  • 截至2024年3月31日的三個月,基本報表EBITDA爲負120萬美元,與2023年3月31日的三個月負180萬美元相比。
  • 截至2024年3月31日的三個月,調整後的基本報表EBITDA爲負100萬美元,相比於2023年3月31日的三個月的負110萬美元。

DEFINITION AND RECONCILIATION OF NON-IFRS FINANCIAL MEASURES
The Company reports certain non-IFRS measures that are used to evaluate the performance of its businesses and the performance of their respective segments. Securities regulators require such measures to be clearly defined and reconciled with their most comparable IFRS measures.

非IFRS財務指標的定義和調解
公司報告了某些用於評估其業務績效和各自業務板塊績效的非IFRS指標。證券監管機構要求這些指標與其最相似的IFRS指標明確界定和調解。

As non-IFRS measures generally do not have a standardized meaning, they may not be comparable to similar measures presented by other issuers. Rather, these are provided as additional information to complement those IFRS measures by providing further understanding of the results of the operations of the Company from management's perspective. Accordingly, these measures should not be considered in isolation, nor as a substitute for analysis of the Company's financial information reported under IFRS. Non-IFRS measures used to analyze the performance of the Company's businesses include "EBITDA" and "Adjusted EBITDA".

由於非IFRS指標通常沒有標準化的含義,它們可能與其他發行人提出的類似指標不可比較。相反,這些指標提供了補充信息,以提供管理層從管理角度進一步了解公司業務板塊的運營結果,以補充那些IFRS指標,因此不能孤立地考慮這些指標,也不能替代對公司根據IFRS報告的財務信息進行分析。用於分析公司業務板塊績效的非IFRS指標包括“基本報表EBITDA”和“調整後的基本報表EBITDA”。

The Company believes that these non-IFRS financial measures provide meaningful supplemental information regarding the Company's performances and may be useful to investors because they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making. These financial measures are intended to provide investors with supplemental measures of the Company's operating performances and thus highlight trends in the Company's core businesses that may not otherwise be apparent when solely relying on the IFRS measures. These non-IFRS measures are calculated as follows:

公司認爲,這些非IFRS財務指標提供了與公司業績有關的有意義的補充信息,並且可能對投資者有用,因爲它們允許更透明地了解管理層在其財務和運營決策中使用的關鍵指標。這些財務指標旨在爲投資者提供補充的公司運營績效指標,因此在僅依靠IFRS指標進行分析時,可能會凸顯公司核心業務板塊的趨勢。這些非IFRS指標的計算方式如下:

"EBITDA" is comprised as income (loss) less interest, income tax and depreciation and amortization. Management believes that EBITDA is a useful indicator for investors, and is used by management, in evaluating the operating performance of the Company. See "Consolidated EBITDA and Adjusted EBITDA Reconciliation" appended to this press release for a quantitative reconciliation of EBITDA to the most directly comparable financial measure.

"基本報表EBITDA"由收入(損失)減去利息、所得稅和折舊及攤銷組成。管理層認爲EBITDA是投資者評估公司運營績效的有用指標,並在評估公司的運營績效時使用。有關EBITDA與最直接可比財務指標的數量調解,請參見附錄於本新聞稿的“綜合基本報表EBITDA和調整後的基本報表EBITDA調和表”。

"Adjusted EBITDA" is comprised as income (loss) less interest, income tax, depreciation, amortization, share-based compensation, Brand Fund revenue and expense timing difference, change in fair value of warrant liability, foreign exchange gain (loss) and other income / expenses not attributable to the operations of the Company. Management believes that EBITDA is a useful indicator for investors, and is used by management, in evaluating the operating performance of the Company. See "Consolidated EBITDA and Adjusted EBITDA Reconciliation" appended to this press release for a quantitative reconciliation of Adjusted EBITDA to the most directly comparable financial measure.

"調整後的基本報表EBITDA"由收入(損失)減去利息、所得稅、折舊、攤銷、按股份計算的補償、品牌基金收入和費用時間差異、認股權責任準備金價值變化、匯率損益和其他與公司業務無關的收入/費用組成。管理層認爲EBITDA是投資者評估公司運營績效的有用指標,並在評估公司的運營績效時使用。請參見附錄於本新聞稿的“綜合基本報表EBITDA和調整後的基本報表EBITDA調和表”,了解調整後的基本報表EBITDA與最直接可比財務指標的數量調解。

A reconciliation of how the Company calculates EBITDA and Adjusted EBITDA is provide in the table appended to this press release.

公司計算EBITDA和調整後的基本報表EBITDA的調和表在附錄於本新聞稿中。

For more information, please see the audited annual Financial Statements (the "Financial Statements") and the annual Management Discussion & Analysis of the Company (MD&A") under the Company's profile at .

有關更多信息,請在公司的個人資料下查看經審計的年度基本報表和公司的管理層討論與分析(MD&A)。

About ARCpoint Inc.
ARCpoint is a leading US-based franchise system that leverages technology along with brick-and-mortar locations to give businesses and individual consumers access to convenient, cost-effective healthcare information and solutions with transparent, up-front pricing, so that they can be proactive and preventative with their health and well-being. ARCpoint is based in Greenville, South Carolina, USA. ARCpoint Franchise Group LLC, formed under the laws of the state of South Carolina in February 2005, is the franchisor of ARCpoint Labs and supports over 130 independently owned locations. ARCpoint sells franchises to individuals throughout the United States and provides support in the form of marketing, technology and training to new franchisees. ARCpoint Corporate Labs LLC develops corporate-owned labs committed to providing accurate, cost-effective solutions for customers, businesses and physicians. AFG Services LLC serves as the innovation center of the ARCpoint group of companies as it builds a proprietary technology platform and a physician network to equip all ARCpoint labs with best-in-class tools and solutions to better serve their customers. The platform also digitalizes and streamlines administrative functions such as materials purchasing, compliance, billing and physician services for ARCpoint franchise labs and other clients.

關於ARCpoint Inc.
ARCpoint是一家領先的美國特許經營體系,利用技術以及實體位置,爲企業和個人消費者提供方便、經濟實惠、透明和前期確定的醫療保健信息和解決方案,以便他們在健康和幸福方面採取積極和預防性措施。ARCpoint總部位於美國南卡羅來納州的格林維爾市。成立於2005年2月的ARCpoint Franchise Group LLC根據南卡羅來納州法律成立,是ARCpoint Labs的特許經營人,並支持超過130個獨立擁有的位置。ARCpoint將特許經營權出售給美國各地的個人,並向新特許經營人提供市場營銷、技術和培訓支持。ARCpoint Corporate Labs LLC創建了公司擁有的實驗室,致力於爲客戶、企業和醫生提供準確、經濟實惠的解決方案。AFG Services LLC作爲ARCpoint公司集團的創新中心,正在構建專有的技術平台和醫生網絡,爲所有ARCpoint實驗室提供最佳工具和解決方案,以更好地服務於他們的客戶。該平台還將數字化和簡化行政功能,如物料採購、合規、賬單和醫生服務,以服務於ARCpoint特許經營實驗室和其他客戶。

For more information, please contact:

更多信息,請聯繫:

ARCpoint Inc.
Jason Tong, Chief Financial Officer
Phone : (604) 889-7827
E-mail : invest@arcpointlabs.com

ARCpoint Inc.
財務總監Jason Tong
電話:(604) 889-7827
電子郵件:invest@arcpointlabs.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION :

關於前瞻性信息的謹慎聲明:

Forward-Looking Information – this news release contains "forward-looking information" within the meaning of applicable Canadian securities laws which are based on ARCpoint's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.

前瞻性信息–本新聞發佈包含基於ARCpoint的當前內部預期、估計、投影、假設和信仰和對未來事件的觀點的“前瞻性信息”。前瞻性信息可以識別出具有前瞻性的術語,例如“期望”、“可能”、“可能”、“將”、“應該”、“打算”、“預期”、“估計”和其他類似的詞語,包括其負面和語法變化,或表明某些事件或情況“可能”、“可能”或“將”發生,或通過討論策略。

The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Froward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the ability of the Company to implement its business strategies, the COVID-19 pandemic; competition and other risks.

本新聞發佈中的前瞻性信息是基於管理層認爲在相應情況下合理的預期、估計、投影、假設和未來事件的觀點。前瞻性信息包括估計、計劃、期望、意見、預測、投影、目標、指導或其他不是事實陳述的聲明。前瞻性信息需涉及已知和未知風險,包括但不限於普遍經濟情況;不利行業事件;市場失去;未來立法和監管發展;無法從內部和外部來源獲得足夠資金,和/或無法獲得有利的條件的足夠資金;公司實施其業務策略的能力,COVID-19大流行;競爭和其他風險。

Any forward-looking information speaks only as of the date on which it is made, and except as required by law, the Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all such factors. When considering the forward-looking information contained herein, readers should keep in mind the risk factors and other cautionary statements in the Company's disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at . The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.

任何前瞻性信息僅至於其發出日期,並且除非法律要求,公司不承擔更新或修訂任何前瞻性信息的任何義務,無論是因爲新信息、未來事件還是其他任何原因。新因素不斷出現,公司無法預測所有這些因素。在考慮本文中的前瞻性信息時,讀者應謹記公司在S EDA R上向適用的加拿大證券監管機構披露文件中的風險因素和其他警示性聲明。披露文件中的風險因素和其他因素可能導致實際事件或結果與任何前瞻性信息所述的事件或結果有實質性不同。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this Press release.

TSX創業板交易所及其監管服務提供商(在該交易所的政策中定義爲該術語)不接受對本新聞發佈的充分性或準確性的責任。

ARCpoint Inc.
Consolidated EBITDA and Adjusted EBITDA Reconciliation
(Expressed in United States Dollars)

ARCpoint Inc.
合併息稅折舊及攤銷前EBITDA和調整後EBITDA對比表
(以美元表示)

(a) Finance expense comprised of interest on bank loans, notes payable and lease liabilities (see Financial Statements).
(b) Share-based compensation expense comprised of non-cash compensation (see Financial Statements).
(c) Other income comprised of government assistance benefit received pertaining to the COVID-19 pandemic.
(d) The Group operates a Brand Fund established to collect and administer funds contributed for use in advertising and promotional programs designed to increase sales and enhance the reputation of the Group and its franchisees. The Group reports contributions and expenditures on a gross basis on the Group's statement of profit and loss. Brand Fund contributions are recognized as revenue when invoiced, as the Group has full discretion on how and when the Brand Fund revenues are spent. Brand Fund revenue received may not equal advertising expenditures for the period due to timing of promotions and this difference is recognized to earnings. This adjustment is made to normalize for the timing difference of the Brand Fund revenues and Brand Fund expenditures.

(a)資金成本包括銀行貸款、應付票據和租賃負債的利息(見基本報表)。
(b)股票期權獎勵支出包括非現金獎勵(見基本報表)。
(c)其他收入包括與COVID-19大流行相關的政府援助金。
(d)本集團設有一個品牌基金,用於收集和管理用於廣告和促銷計劃的基金,旨在增加本集團及其特許經營權人的銷售量和聲譽。本集團在利潤或損益表上按總額報告所籌集的款項和支出。在發票已開出的情況下,品牌基金的捐款將被認定爲收入,因爲本集團對品牌基金收入如何和何時支出完全自主。由於促銷的時機不同,品牌基金收入可能與期間的廣告支出不相等,此差異被認定爲收益。這種調整是爲了平衡品牌基金收入和品牌基金支出的時差。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論